Dressings Patents (Class 424/445)
-
Publication number: 20140056957Abstract: Methods and compositions are provided for generating and applying long-lasting therapeutic nitric oxide (NO) gas from the reaction of water-soluble chemical reactants microencapsulated in polymer matrices. In some applications the microencapsulated reactants are introduced in an aqueous gel, and in other applications they are introduced to the area of therapy either directly or in a medical device such as a therapeutic pad or dressing. In some applications, the microencapsulated chemical precursors are maintained in close physical proximity to one another in a limited volume, and using a limited amount of solvent residing within that same volume to extract and process the chemical precursors to form NO.Type: ApplicationFiled: August 16, 2013Publication date: February 27, 2014Applicant: NIOXX LLCInventors: Cheng-Shing Chen, Ferid Murad, Kenneth A. Smith, WIlliam A. Seitz, William J. Merrell, Alexandru T. Balaban
-
Publication number: 20140050774Abstract: The wound treatment therapy deactivates pathogenic microorganisms within the wound environment without disrupting the cell walls. The wound treatment therapy of this invention combines the application of stabilized hypochlorous acid compound with the application of a hydrophobic wound dressing. The application of hypochlorous acid provides the initial anti-microbial agent, which disrupts and eradicates biofilm, as well as, deactivates the harmful pathogenic organisms within the wound environment. The application of the hydrophobic wound dressing, which is designed to bind harmful hydrophobic microorganisms and toxins, provides a mechanical vehicle for physically removing deactivated hydrophobic microorganisms form the wound environment with each dressing change.Type: ApplicationFiled: October 23, 2013Publication date: February 20, 2014Applicant: INTEGRATED HEALING TECHNOLOGIES, LLCInventors: ALBERT RODEWALD, ROBERT STEPHEN PORTER
-
Patent number: 8652509Abstract: A pharmaceutical composition and method for topical wound treatment by topical treatment with gallium salts, preferably gallium nitrate. In a preferred embodiment, the gallium nitrate is in an aqueous form without coagulation inhibitors such as citrate. The aqueous gallium salt formulation may be administered by a variety of methods including spraying, topical lotions, topical foams, and/or bandages containing or packaged with breakable ampoules of aqueous gallium salt formulations, and liquid bandage formulations. The aqueous gallium salt formulation may additionally contain other active and inactive ingredients, such as viscosity modifying agents, foaming agents, antiseptics, antibiotics, enzymes, fibrinogen, fibrin, polymers and growth factors.Type: GrantFiled: October 24, 2010Date of Patent: February 18, 2014Inventor: Moshe Rogosnitzky
-
Patent number: 8652293Abstract: A moisture-curable and biodegradable adhesive that includes the reaction product of: (a) an isocyanate component having an average functionality of at least 2; (b) an active hydrogen component having an average functionality greater than 2.1; and (c) an ionic salt component having an average hydroxyl or amino functionality, or combination thereof, of at least 1.Type: GrantFiled: April 5, 2012Date of Patent: February 18, 2014Assignee: Cohera Medical, Inc.Inventors: Jason Smith, Eric Beckman
-
Publication number: 20140044770Abstract: Compositions and methods for increasing or decreasing DNA repair are provided. Composition includes a Brd4 polypeptide, fragment, fusion, or variant thereof. The fusion protein can include a protein transduction, a targeting domain, or a combination thereof to enhance delivery of the fusion protein to the interior of a particular target cell, such as a cancer cell. Inhibitory nucleic acids that target a Brd4 mRNA and antibodies that target a Brd4 polypeptide are also disclosed. The inhibitory nucleic acid or antibody can target a sequence or epitope on Brd4 isoform B that is absent on Brd4 isoform A and Brd4 isoform C. Methods for increasing or decreasing the sensitivity of cells to a DNA damaging agent, methods of treating cancer, and methods of determining cells' sensitivity to a DNA damaging agent are also disclosed.Type: ApplicationFiled: July 18, 2013Publication date: February 13, 2014Inventors: Michael B. Yaffe, Scott R. Floyd
-
Publication number: 20140046276Abstract: The present invention pertains to use of sodium diacetate (NaHAc2) as an antimicrobial agent against bacteria growing in biofilms. The aspects of the invention include a wound care product comprising sodium diacetate, a kit comprising a wound care product, and a method of treating an infected wound.Type: ApplicationFiled: April 18, 2012Publication date: February 13, 2014Applicants: RIGSHOSPITALET COPENHAGEN UNIVERSITY HOSPITAL, BISPEBJERG HOSPITAL, DANMARKS TEKNISKE UNIVERSITETInventors: Thomas Bjarnsholt, Klaus Kirketerp-Moller, Michael Christian Givskov
-
Patent number: 8647647Abstract: A topical formulation for application to exposed body tissue, the formulation comprising a silver(II) oxide and zinc oxide, intimately dispersed within a carrier medium.Type: GrantFiled: July 21, 2010Date of Patent: February 11, 2014Assignee: Aidance Skincare and Topical Solutions, LLCInventor: Perry Antelman
-
Patent number: 8647662Abstract: The invention is directed to a wound healing device. Such wound healing device utilizes novel wound healing compositions embedded onto or into a natural plant-derived cloth-based matrix.Type: GrantFiled: November 13, 2012Date of Patent: February 11, 2014Assignee: Stemnion, Inc.Inventors: David L. Steed, Linda O. Palladino
-
Patent number: 8647663Abstract: The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.Type: GrantFiled: November 14, 2012Date of Patent: February 11, 2014Assignee: Stemnion, Inc.Inventors: David L. Steed, Randall G. Rupp, Howard C. Wessel
-
Patent number: 8637072Abstract: The present invention relates to wound dressings, in particular to an antibacterial wound dressing based on silvered gel-forming fabric and to a process for the manufacture of such a wound dressing.Type: GrantFiled: March 18, 2009Date of Patent: January 28, 2014Assignee: Convatec Technologies, Inc.Inventors: David Kershaw, Barry DeBoorder, Stephen John Law
-
Patent number: 8623387Abstract: Disclosed is an external preparation composition having good transdermal absorbability. An external preparation composition having excellent transdermal absorbability can be produced by dissolving a medicinal substance or a salt thereof in a fatty acid-based ionic liquid to form a composite ionic composition of the medicinal substance. The external preparation composition can be used as a liquid preparation, an ointment, a cream, a plaster or the like, and enables to provide a preparation having excellent transdermal absorbability.Type: GrantFiled: November 20, 2008Date of Patent: January 7, 2014Assignee: Medrx Co., Ltd.Inventors: Toshikazu Yamaguchi, Kenta Kawai, Katsuhiro Yamanaka, Noboru Tatsumi
-
Publication number: 20130344129Abstract: The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally, a cellular adhesion peptide covalently attached to the polymer. The hydrophilic polymer may be a glycosaminoglycan such as hyaluronan. The cellular adhesion peptide may be linear RGD peptide sequence covalently attached to the polymer. The ligand binding moiety may be a monoclonal antibody covalently attached to the polymer. The antibody may be selected from the group consisting of an anti-IL-1?, an anti-IL-6, an anti-TNF-?, and combinations thereof. The polymer functions as a substrate or matrix for cell migration and tissue regeneration.Type: ApplicationFiled: August 17, 2013Publication date: December 26, 2013Applicant: CARNEGIE MELLON UNIVERSITYInventors: Newell R. WASHBURN, Sidi Ahmed BENCHERIF, Liang Tso SUN
-
Publication number: 20130344130Abstract: A smart antimicrobial material and dressing to inhibit microbial growth is provided. Endogenous chemicals, such as metabolites produced from bacteria are utilized as chemical substrates and converted by enzymes to produce a disinfecting compound that will in turn inhibit the targeted microorganism. The material shall remain passive until such time as it encounters a microbe which expresses and/or secretes specific metabolites or markers. The enzyme or enzymes embedded in the smart material converts the metabolite into a disinfecting compound, which in turn either kills the microorganism or prevents it from multiplying on the surface of the material.Type: ApplicationFiled: June 12, 2013Publication date: December 26, 2013Inventors: Anna M. Leech, Jeremy P. Walker, Scott Donahue, Jermaine D. Johnson, Jessica J. Sinclair
-
Publication number: 20130337037Abstract: The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to treat wounds. More specifically the present invention relates to hemostatic compositions that reduce the need for, and cost of, nursing care of patients with chronic wounds by reducing the frequency of wound dressing changes.Type: ApplicationFiled: July 31, 2013Publication date: December 19, 2013Applicant: Marine Polymer Technologies, Inc.Inventors: Sergio Finkielsztein, John N. Voumakis
-
Patent number: 8609132Abstract: A flow directing material includes a substrate. The substrate includes a first region that exudes fluid under a compressive or tensile load and a second region that imbibes fluid under the compressive or tensile load. The first region has a first porosity and a first permeability and the second region has a second porosity and a second permeability. The first permeability and the second permeability are about 10?13 m2 to 105 m2. The first porosity and the second porosity are about 0.3 to about 0.7. The first porosity and the second porosity are at least about 5% different.Type: GrantFiled: April 21, 2008Date of Patent: December 17, 2013Assignee: Case Western Reserve UniversityInventors: Melissa Knothe Tate, Eric Anderson
-
Patent number: 8609130Abstract: The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal fibers; flax fibers; soybean fibers; corn fibers; hemp fibers; lyocel fibers; wool; lactide and/or glycolide polymers; lactide/glycolide copolymers; silicate fibers; polyamide fibers; feldspar fibers; zeolite fibers, zeolite-containing fibers, acetate fibers; and combinations thereof; the hemostatic textile capable of activating hemostatic systems in the body when applied to a wound. Additional cofactors such as thrombin and hemostatic agents such as RL platelets, RL blood cells; fibrin, fibrinogen, and combinations thereof may also be incorporated into the textile. The invention is also directed to methods of producing the textile, and methods of using the textile to stop bleeding.Type: GrantFiled: September 14, 2012Date of Patent: December 17, 2013Assignees: The University of North Carolina at Chapel Hill, Entegrion, Inc.Inventors: Thomas H. Fischer, E. Stan Eskridge, Jr., William M. Malloy, Jr., Malloy Evans
-
Patent number: 8609129Abstract: A hemostatic agent composition, delivery system and method include a hemostatic agent composition which is inert and non-reactive relative to blood clotting proteins and platelets. The composition includes a clay material combined with a humectant in a stable suspension embedded in a mesh fabric and, when dried, is capable of accelerating the formation of a stable clot when applied to an actively bleeding wound or drying other bodily fluids.Type: GrantFiled: March 8, 2010Date of Patent: December 17, 2013Inventors: Jack Mentkow, Lisa Mentkow
-
Patent number: 8609131Abstract: An absorbent dressing is described which comprises a crosslinked hydrophilic gel absorbent layer comprising a first component polymer comprising a plurality of polymerized monomer units having pendent hydrophilic groups, and pendent Michael donor groups; and a crosslinking agent comprising at least two Michael acceptor groups.Type: GrantFiled: January 25, 2005Date of Patent: December 17, 2013Assignee: 3M Innovative Properties CompanyInventors: David J. Plaut, Duane D. Fansler, Kevin M. Lewandowski, Babu N. Gaddam
-
Publication number: 20130330397Abstract: Methods have been developed for incorporation of a peracid compound into or on wound application matrices, such as bandages or dressings, and other matrices which will favorably impact wound healing and help eliminate microbial infection. The peracid compound comprises a base compound that is metabolically pertinent to wound healing, the oxidized form of the base compound (a peracid), and an appropriate oxidizer, such as hydrogen peroxide. In addition, other excipients with wound healing potential, such as esters of the base compound, may be added to the peracid compound. The combination peracid-wound application matrices can be used to disinfect and heal various wound types with designed time release of the peracid compound.Type: ApplicationFiled: August 14, 2013Publication date: December 12, 2013Applicant: CHD Bioscience, Inc.Inventors: Edwin D. Neas, Michael K. Handley, Kevin S. Marchitto, Steve T. Flock
-
Publication number: 20130315979Abstract: The present invention relates to a glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×105 g/mol and existing in gel form in aqueous solution at a concentration ?1% at 25° C. and neutral pH and having a melting temperature (gel to sol) of 35 to 60° C. when the glucan is dissolved in water at a concentration of 2%, methods for the production thereof, medical uses thereof, physical supports having the glucan applied thereto or impregnated thereon and in vitro methods of proliferation of skin cells which comprise contacting a population of skin cells with the glucan.Type: ApplicationFiled: November 29, 2011Publication date: November 28, 2013Applicant: Biotec Pharmacon ASAInventors: Rolf Engstad, Stein-Tore Solem, Dag-Eirik Ramsøy
-
Patent number: 8591940Abstract: A method of treating scar tissue by applying a composite sheet for delivering therapeutic agents to the skin is disclosed. The composite sheet comprises a flexible porous polymer for holding and releasing the therapeutic agent in a polymer enrobing material. Microchannels pass through the polymer enrobing material and flexible porous polymer to promote the release of the therapeutic agent. The composite sheet is capable of releasing the therapeutic agent for periods of about 0 to about 30 days.Type: GrantFiled: December 20, 2007Date of Patent: November 26, 2013Assignee: New Medical Technology Inc.Inventors: Haitham Matloub, Wilfred Lynch
-
Publication number: 20130309286Abstract: The present invention relates to a gel composition comprising a glucan and a gelling agent, said composition having a melting point (gel to sol) above 37° C., as well as to the uses of this composition in therapy, in particular in wound healing.Type: ApplicationFiled: November 29, 2011Publication date: November 21, 2013Applicant: BIOTEC PHARMACON ASAInventors: Rolf Engstad, Dag-Eirik Ramsoy, Erik Steene
-
Publication number: 20130310779Abstract: High-pressure bleeding wounds (and other bleeding wounds) may be treated by applying direct pressure directly in the bleeding wound, such as by applying a back pressure in a confined space around and in the wound. Certain substances and articles may be inserted into the wound, and the wound may be enclosed with that substance or article (such as a hemostatic substance, which may be polymeric), by swelling on contact with molecules (such as water molecules in the blood) encountered in the wound, generates the desired pressure to stop or at least reduce the bleeding without the detrimental effects of a tourniquet. Clot-inducing substances may be introduced into the wound contemporaneously with direct pressure application directly in the wound. Compressible and non-compressible wounds are treated. Treatment stops bleeding without producing pressure injury or ischemic damage. Medical devices using this technology are provided, including removable, biodegradable, medic-administrable devices.Type: ApplicationFiled: July 26, 2013Publication date: November 21, 2013Applicant: Virginia Commonwealth UniversityInventors: Gary Wnek, Marcus E. Carr, JR., Gary Bowlin, Kelman I. Cohen, Kevin R. Ward, Wayne Barbee, Rao Ivatury
-
Patent number: 8586078Abstract: Oil-in-water emulsion gels and medical articles containing an omega-3 oil are disclosed. Also disclosed are methods of preparing and using such emulsion gels and medical articles.Type: GrantFiled: December 5, 2006Date of Patent: November 19, 2013Assignee: RBA Pharma Inc.Inventors: Marie-Pierre Faure, Kirill Shingel
-
Patent number: 8586080Abstract: Compositions and methods for the continuous and controlled transdermal delivery of an active agent from a pharmaceutically acceptable carrier composition comprising a polyoxazoline polymer, wherein the active drug incorporated in the carrier composition of the transdermal system remains substantially solubilized and stable during storage prior to use.Type: GrantFiled: October 28, 2004Date of Patent: November 19, 2013Assignee: Noven Pharmaceuticals, Inc.Inventors: Rod Hartwig, David Kanios
-
Publication number: 20130296761Abstract: There is provided a gel sheet that has high biocompatibility and safety, can contain both a hydrophilic medicinal agent and a hydrophobic medicinal agent, and provides an excellent feel in use during the application onto human skin or others. A gel sheet including: a lipid peptide gelator including a low molecular weight lipid peptide having a molecular weight of 1,000 or less or a pharmaceutically usable salt of the lipid peptide; and a polymeric compound, wherein the polymeric compound is included in an amount of more than 1% (w/w) and less than 50% (w/w) with respect to the total mass of the gel sheet.Type: ApplicationFiled: November 11, 2011Publication date: November 7, 2013Applicants: KYUSHU UNIVERSITY, NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Masahiro Goto, Takayuki Imoto, Tsubasa Kashino, Takehisa Iwama, Nobuhide Miyachi
-
Publication number: 20130287837Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.Type: ApplicationFiled: March 15, 2013Publication date: October 31, 2013Inventors: Martin MacPhee, Dawson Beall
-
Publication number: 20130280321Abstract: A method of inducing hemostasis in a wound using a hemostatic product. A dextran support is provided. At least one hemostatic agent stabilizer is mixed with at least one hemostatic agent to form a hemostatic agent and stabilizer mixture. The at least one hemostatic agent includes at least one of thrombin and fibrinogen. The hemostatic agent and stabilizer mixture is associated with the dextran support. The hemostatic product is applied to the wound in which a bodily fluid is present. The at least one hemostatic agent is released from the hemostatic product to induce hemostasis in the wound.Type: ApplicationFiled: June 18, 2013Publication date: October 24, 2013Inventors: Curtis E. Olson, Philip A. Messina
-
Patent number: 8563800Abstract: A sacral wound dressing having a bottom end with three substantially V-shaped projections. In use, a protective layer of the wound dressing is removed to expose an adhesive layer and an absorbent layer, the wound dressing is folded over on itself substantially along a central axis, a medial V-shaped projection is inserted into a superior portion of the gluteal cleft of the person to adhere the medial projection to the skin within the gluteal cleft, two lateral V-shaped projections are then pushed against a superior portion of the buttocks of the person to adhere the lateral projections to the skin, and the opposing lateral ends and the top end of the wound dressing are then pushed against the skin of the person until the wound dressing is properly adhered to the sacrococcygeal region over the sacral wound.Type: GrantFiled: November 17, 2009Date of Patent: October 22, 2013Inventor: Patricia A. Smith
-
Patent number: 8557278Abstract: An apparatus for promoting the clotting of blood and controlling bleeding comprises a receptacle for retaining blood clotting material in particulate form therein. A pad for controlling bleeding comprises a mesh structure and a support attached to the mesh structure to facilitate the application of pressure to the pad and the wound. A bandage applicable to a bleeding wound comprises a mesh structure and a flexible substrate attached to the mesh structure, the substrate being a cloth or plastic member that may be adhesively attachable to cover a wound. In any embodiment, at least a portion of the receptacle or mesh structure is defined by a mesh having openings therein, and at least a portion of the particulate blood clotting material is in direct contact with blood. The mesh may include a zeolite powder impregnated or otherwise incorporated therein.Type: GrantFiled: August 27, 2012Date of Patent: October 15, 2013Assignee: Z-Medica, LLCInventors: Raymond J. Huey, Jeffrey L. Horn
-
Patent number: 8551519Abstract: Novel bioabsorbable and/or biocompatible polyurethanes, polyureas, polyamideurethanes and polyureaurethanes with tunable physical, mechanical properties and hydrolytic degradation profiles are provided for use in biomedical applications such as stents, stent coatings, scaffolds, foams, and films. The disclosed polymers may be derived from biocompatible and/or bioabsorbable polyisocyanates. The present invention also relates to new and improved methods for the preparation of the biocompatible and/or bioabsorbable polyisocyanates.Type: GrantFiled: November 26, 2012Date of Patent: October 8, 2013Assignee: Bezwada Biomedical, LLCInventor: Rao S Bezwada
-
Publication number: 20130261526Abstract: Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer, particularly a hydrophobic pressure-sensitive adhesive (PSA), a plasticizing elastomer, a tackifying resin, and an optional antioxidant. The discontinuous hydrophilic phase, if present, is composed of a crosslinked hydrophilic polymer, particularly a crosslinked cellulosic polymer such as crosslinked sodium carboxymethylcellulose. For those hydrogel compositions containing a continuous hydrophilic phase, the components of the phase include a cellulose ester composition or an acrylate polymer or copolymer, and a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding thereto.Type: ApplicationFiled: May 10, 2013Publication date: October 3, 2013Applicants: CORIUM INTERNATIONAL, INC., A.V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESIS, RUSSIAN ACADEMY OF SCIENCESInventors: Gary W. Cleary, Shoreh Parandoosh, Mikhail M. Feldstein, Anatoly E. Chalykh, Nicolai A. Platè, Valery G. Kulichikhin
-
Publication number: 20130251782Abstract: The present invention relates to formulations of ingenol mebutate and methods of preparation and use thereof. More specifically, the invention relates to formulations of ingenol-3-mebutate applied to the skin with occlusion, and methods for treating or preventing diseases or conditions.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Applicant: Leo Laboratories LimitedInventors: Lotte Groth Ladefoged, Per-Ola Arvidsson, Karsten Petersson
-
Publication number: 20130251774Abstract: Novel antimicrobial compositions and coatings are disclosed. The antimicrobial compositions consist of mixtures of taurolidine and protamine, including protamine salts. The antimicrobial compositions are particularly useful in coatings for implantable medical devices. The antimicrobial compositions are effective against a broad spectrum of microbes.Type: ApplicationFiled: May 22, 2013Publication date: September 26, 2013Applicant: Ethicon, Inc.Inventors: Joerg Priewe, Xintian Ming
-
Publication number: 20130243847Abstract: Creatinine, creatinine precursors or the pharmaceutically acceptable salts thereof are activated to function as an antibacterial agent which has broad spectrum activity and is beneficially used in a variety of applications, such as antimicrobial wound dressings, compositions for topical delivery of the antibacterial agent and for preventing and/or inhibiting the occurrence or spread of bacterial infection, as well as the growth of odor-causing bacteria, to name a few.Type: ApplicationFiled: May 1, 2013Publication date: September 19, 2013Applicant: Board of Regents of the University of NebraskaInventors: Thomas McDonald, Steven Tracy, Annika Weber
-
Patent number: 8535710Abstract: A method for treating a wound, and a dressing for wound care management comprising a three-dimensional body of glass-based fibers comprising one or more glass-formers selected from the group consisting of P2O5, SiO2, and B2O3; at least about 25 wt % of the fibers have a diameter between about 200 nm and about 4000 nm, and a length:width aspect ratio of at least about 10. In another form, the glasses are in the form of particles in an ointment or cream applied to a wound. In yet other forms the glasses are employed as fibers formed into sutures for closing a wound, or as particles in a surgical glue for closing a wound.Type: GrantFiled: April 9, 2012Date of Patent: September 17, 2013Assignee: The Curators of the University of MissouriInventors: Steven B. Jung, Delbert E. Day
-
Patent number: 8529941Abstract: Methods and apparatus for a free-standing biodegradable patch suitable for medical applications, especially intravascular, minimally-invasive and intraoperative surgical applications are provided, wherein the patch comprises a free-standing film or device having a mixture of a solid fibrinogen component and a solid thrombin component that, when exposed to an aqueous environment, undergoes polymerization to form fibrin. In alternative embodiments the patch may comprise a solid fibrinogen component, with or without an inorganic calcium salt component. The patch may take a non-adherent form during delivery to a target location within a vessel or tissue, and thereafter may be activated to adhere to vessel wall or tissue, and may include a number of additives, including materials to improve the mechanical properties of the patch, or one or more therapeutic or contrast agents.Type: GrantFiled: September 17, 2010Date of Patent: September 10, 2013Assignee: Bioinspire Technologies, Inc.Inventors: Dorna Hakimimehr, Raoul Bonan
-
Patent number: 8529942Abstract: A wound care dressing comprising one or more nonwoven blankets, where each nonwoven blanket comprises a plurality of fibers, where each of the plurality of fibers are formed from one or more saccharides in optional combination with one or more medicaments.Type: GrantFiled: March 28, 2011Date of Patent: September 10, 2013Inventor: David M. Dixon
-
Patent number: 8524272Abstract: Devices for administration of one or more active agents to the skin or mucosa of a host are formed in the nature of a double-disk patch. One outer layer functions as the primary adhesive layer for adhering the patch to the host. The other inner layer contains at least one active agent to be administered to the host. The inner layer is bonded to the outer layer through an opening provided in an interposed active agent impermeable release layer. The release layer separates a circumferential portion of the active agent containing inner layer from the outer adhesive layer to inhibit migration of the active agent therebetween.Type: GrantFiled: August 15, 2003Date of Patent: September 3, 2013Assignee: Mylan Technologies, Inc.Inventor: Kenneth J. Miller, II
-
Patent number: 8524271Abstract: A skin wound dressing is disclosed. The skin wound dressing comprises Tremella polysaccharide and alginate and is used to cover on a skin wound to accelerate wound healing. The Tremella polysaccharide is isolated from a hot water extract of Tremella fuciformis. The skin wound dressing is a Tremella polysaccharide composite fiber, a Tremella polysaccharide sponge or a Tremella polysaccharide hydrogel.Type: GrantFiled: July 11, 2011Date of Patent: September 3, 2013Assignee: Agricultural Research InstituteInventor: Shu-Hui Yang
-
Patent number: 8524270Abstract: Disclosed is a biocompatible, hemostatic, cross-linked gelatin composition comprising a biocompatible material comprising cross-linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the sponge in the presence of an aqueous solution.Type: GrantFiled: May 22, 2012Date of Patent: September 3, 2013Assignee: Boston Scientific Scimed, Inc.Inventor: Richard J. Greff
-
Patent number: 8512743Abstract: An apparatus for promoting the clotting of blood and controlling bleeding comprises a receptacle for retaining molecular sieve material in particulate form therein. A pad for controlling bleeding comprises a mesh structure and a rigid or semi-rigid support attached to the mesh structure to facilitate the application of pressure to the pad and the wound. A bandage applicable to a bleeding wound comprises a mesh structure and a flexible substrate attached to the mesh structure, the substrate being a cloth or plastic member that may be adhesively attached to cover a wound. In any embodiment, at least a portion of the receptacle or mesh structure is defined by a mesh having openings therein, and at least a portion of the particulate molecular sieve material is in direct contact with blood.Type: GrantFiled: August 29, 2012Date of Patent: August 20, 2013Assignee: Z-Medica, LLCInventors: Jeffrey Horn, Raymond Huey
-
Patent number: 8512729Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: GrantFiled: October 31, 2012Date of Patent: August 20, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian-Wallis
-
Patent number: 8512740Abstract: A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of thrombin, will rest on a vertical surface without dripping. The wound dressing may also be formulated for its ability to continue migration of healing substances, such as PDGF, from the dressing to the wound site. Thrombin substitutes, such as other clotting proteins, may be used instead of thrombin. The resulting foam may also be lyophilized or ground and lyophilized for later reconstitution. A therapeutic drug or other additive may also be added to the wound dressing. A fibrin foam may be made by injecting fibrinogen foam into a clotting protein, such as thrombin.Type: GrantFiled: March 26, 2008Date of Patent: August 20, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventor: Yves A. Delmotte
-
Publication number: 20130195958Abstract: The process in general is based on taking a sample of skin and a sample of blood from the patient and based on these two elements skin is cultured, being placed on a collagen patch to produce a dressing which is subsequently placed on the patient requiring same.Type: ApplicationFiled: May 21, 2010Publication date: August 1, 2013Inventors: Juan Carlos Zambrano Burgl, Jennifer Cristina Gaona Silva
-
Patent number: 8496959Abstract: Methods, system and compositions for making and using a bioresorbable linked dressing made of bioresorbable microspheres in various configurations are provided for use in applying reduced pressure to a wound site. The methods include manufacture of a bioresorbable dressing comprising a casing and bioresorbable microspheres in the form of a rope shape. Further, the casing of the dressing comprises pores formed by a porogen system that may be activated by external to the wound or formed in situ within the wound site. The shape of the dressing allows the dressing to be placed into the wound site such that it fills the shape and size of the wound. Embodiments include formation of various rope dressing and their use in conjunction with reduced pressure therapy.Type: GrantFiled: August 13, 2012Date of Patent: July 30, 2013Assignee: KCI Licensing, Inc.Inventors: Archel Ambrosio, Joanna Payne
-
Publication number: 20130189346Abstract: The instant disclosure relates to a wound dressing, which includes a plurality of hydrogel particles and a dressing. The hydrogel particles are granular colloids capable of absorbing and releasing the fluid, and the hydrogel particles are disposed to fill up the wound entirely. The dressing is covered on the wound to seal the hydrogel particles inside the wound. Thus, the wound dressing can maintain the appropriate balance of moisture in the wound environment to promote healing.Type: ApplicationFiled: January 20, 2012Publication date: July 25, 2013Applicant: SILITECH TECHNOLOGY CORPORATIONInventors: CHI SHENG CHU, CHIN-CHIEN HSIEH, HUNG-RU LIN
-
Publication number: 20130189339Abstract: Medical devices, wound dressings, and methods of dressing wounds are described. Devices and methods using silicone and pharmaceutically active agents are described. Devices including covers and bases are described.Type: ApplicationFiled: March 12, 2013Publication date: July 25, 2013Inventor: David J. Vachon
-
Patent number: 8486442Abstract: An external patch capable of stable prolonged release and transdermal absorption of active ingredient hormones (estrogens and/or progestogens) contained in a pressure sensitive adhesive layer, which external patch ensures low irritation on the skin. In particular, an external patch comprising a support and, superimposed thereon, a pressure sensitive adhesive layer, characterized in that the pressure sensitive adhesive layer comprises, as indispensable components, 5 to 50 wt. % of styrene/isoprene/styrene block copolymer, 20 to 70 wt. % of tackifier resin, 10 to 60 wt. % of softener and 1 to 20 wt. % of polyvinylpyrrolidone and contains, as an active ingredient, estrogen and/or progestogen.Type: GrantFiled: May 13, 2004Date of Patent: July 16, 2013Assignees: Teikoku Seiyaku Co. Ltd., Fuso Pharmaceutical Industries Ltd.Inventors: Kunihiko Matsushita, Kenichi Hattori, Masahiro Yamaji
-
Publication number: 20130171224Abstract: The combination of a first species which is a polyanionic compound and a second species which is an antimicrobial agent is used for the treatment of microbial biofilms and for the topical treatment of wounds. The combination may be incorporated in a wound dressing. The polyanionic compound may be a polyphosphate, such as an alkali metal polyphosphate, e.g. sodium hexametaphosphate. Examples of antimicrobial agents include metallic silver, silver compounds, iodine, PHMB (polyhexamethylene biguanide), acetic acid, chlorhexidine, aminoglycosides (e.g. amikacin, gentamicin, streptomycin and tobramycin), ansamycins, carbacephem, cephalosporins, glycopeptides (e.g. vancomycin), macrolides (eg clarithromycin), monobactams and sulfonamides).Type: ApplicationFiled: January 14, 2011Publication date: July 4, 2013Inventors: Steven Lane Percival, Brian John Hamerslag